The estimated Net Worth of Street Financial S.A. Bay is at least $48.8 Million dollars as of 18 December 2020. Street Bay owns over 1,173,033 units of XBiotech Inc stock worth over $12,820,402 and over the last 5 years Street sold XBIT stock worth over $36,004,889.
Street has made over 3 trades of the XBiotech Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently Street sold 1,173,033 units of XBIT stock worth $22,029,560 on 18 December 2020.
The largest trade Street's ever made was selling 1,662,616 units of XBiotech Inc stock on 19 February 2020 worth over $10,607,490. On average, Street trades about 1,006,162 units every 101 days since 2020. As of 18 December 2020 Street still owns at least 1,981,515 units of XBiotech Inc stock.
You can see the complete history of Street Bay stock trades at the bottom of the page.
Street's mailing address filed with the SEC is MEIERHOFSTRASSE 5, , VADUZ, N2, FL-9490.
Over the last 9 years, insiders at XBiotech Inc have traded over $50,443,920 worth of XBiotech Inc stock and bought 1,428,502 units worth $11,921,113 . The most active insiders traders include Street Financial S.A. Bay, Fondation Rennes, and W Thorpe Mckenzie. On average, XBiotech Inc executives and independent directors trade stock every 48 days with the average trade being worth of $1,053,782. The most recent stock trade was executed by W Thorpe Mckenzie on 16 December 2021, trading 250,000 units of XBIT stock currently worth $2,500,000.
xbiotech is developing a first-in-class monoclonal antibody (mabp1) to inhibit chronic inflammation. chronic (sterile) inflammatory responses are involved in the progression of many serious and common diseases. mabp1 is being investigated in many important areas of medicine, including: cancer, leukemia (phase 1); type 2 diabetes (phase2); psoriasis (phase 2); and vascular disease (phase 2). mabp1 is a true human™ antibody cloned from a natural human immune response and—unlike currently marketed antibodies—it has not undergone any modification to alter its function. it has exhibited the best potential tolerability and safety during the clinical trials. xbiotech has established a current good manufacturing practices (cgmp) program to commercialize its lead product candidate. the company has purchased land and designed a commercial-scale plant with 25,000l total bioreactor capacity. construction of the facility is planned to commence in 4th quarter 2011..
XBiotech Inc executives and other stock owners filed with the SEC include: